aspi_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 6, 2026

 

ASP Isotopes Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-41555

 

87-2618235

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2200 Ross Avenue, Suite 4575E

Dallas, TX

 

75201

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (214) 432-8219

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01

 

ASPI

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

 

 

 

 

Item 7.01  Regulation FD Disclosure.

 

On March 6, 2026, ASP Isotopes Inc. (the “Company”) issued a press release regarding a memorandum of understanding (MOU) between Quantum Leap Energy LLC and a large U.S. energy company regarding evaluation of support to advance the enriched uranium fuel supply chain in the United States, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein (the “Press Release”).

 

The information in this Item 7.01 and in the Press Release shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made by the Company before or after the date hereof, regardless of any general incorporation language in such filing.

 

The Press Release includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

 

Item 9.01  Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release dated March 6, 2026.

104

 

Cover Page Interactive Date File (embedded within the Inline XBRL document)

 

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ASP ISOTOPES INC.

 

 

 

 

Date: March 6, 2026

By:

/s/ Donald G. Ainscow

 

 

Name:

Donald G. Ainscow

 

 

Title:

Executive Vice President,

General Counsel and Secretary

 

 

 
3

 

EXHIBIT 99.1

 

Quantum Leap Energy Enters into Memorandum of Understanding with a Large U.S. Energy Company Regarding Evaluation of Support to Advance Domestic Enriched Uranium Fuel Supply Chain

 

Marks an important step toward enhancing the domestic supply chain for nuclear fuel in the United States

 

Advances QLE’s strategy to build U.S.-based capabilities to support advanced nuclear fuel production

 

DALLAS, TX – March 6, 2026 – ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced that Quantum Leap Energy LLC (“QLE” or the “Company”), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has entered into a non-binding Memorandum of Understanding (MOU) with a large publicly traded U.S. energy company that operates nuclear power stations.

 

Under the terms of the MOU, the U.S. energy company will evaluate options to support QLE’s plans to establish advanced nuclear fuel cycle facilities located in the United States.  These facilities are planned to produce high assay low enriched uranium (HALEU) and low enriched uranium plus (LEU+), as well as to provide uranium conversion and deconversion services.  The MOU outlines potential terms for providing financial support pursuant to definitive agreements for the supply of enriched uranium.

 

QLE believes both HALEU and LEU+ are vital nuclear fuels for the United States.  QLE expects that many advanced nuclear reactors, including small modular reactors, will rely on fuels with higher uranium enrichment levels, specifically HALEU.  QLE also intends to make available LEU+ to the existing fleet of nuclear reactors currently running on LEU, thus enabling existing reactors to lengthen the time between refueling, cut costs and boost power output.  The successful development of U.S.-based advanced nuclear fuel production facilities would represent a significant milestone in strengthening America's domestic nuclear fuel supply chain.

 

“This memorandum of understanding represents an important step in QLE’s efforts to help establish a domestic supply chain for advanced nuclear fuels,” said Ryno Pretorius, Chief Executive Officer of Quantum Leap Energy.  “We believe interest from a major U.S. energy producer underscores the importance of reliable domestic sources of nuclear fuel.  We look forward to advancing technical diligence and evaluating potential pathways toward long-term commercial collaboration.”

 

The MOU comes amid growing urgency to increase U.S.-based uranium enrichment capacity including HALEU production capabilities. With the federal government's ban on Russian uranium imports starting in 2028 and increasing demand from next-generation reactor developers, domestic suppliers are expected to be needed to fill a critical perceived gap in the nuclear fuel supply chain.

 

 
1

 

 

About Quantum Leap Energy

 

Quantum Leap Energy is a development stage nuclear fuels company dedicated to advancing innovative technologies and processes across critical segments of the nuclear fuel cycle. The Company focuses on both front-end activities, including uranium conversion, enrichment of uranium-235 for nuclear fuel production (HALEU, LEU+ and LEU), and isotopic separation of lithium-6 and lithium-7, as well as back-end radioactive waste treatment technologies. Through exclusive global rights to proprietary Aerodynamic Separation Process (ASP) and laser-based Quantum Enrichment (QE) technologies, Quantum Leap Energy aims to address perceived gaps in the nuclear fuel supply chain for advanced nuclear reactors, small modular reactors, and fusion systems. The Company has established strategic partnerships or commercial initiatives and relationships with industry leaders including TerraPower, Fermi America, and the South Africa Nuclear Energy Corporation (Necsa) to accelerate the commercialization of critical isotopes essential for next-generation nuclear energy systems. For additional information, please visit: https://www.qleapenergy.com/.

 

About ASP Isotopes Inc.

 

ASP Isotopes Inc. is a development stage advanced materials company building a differentiated isotope enrichment platform to enhance global supply chain access to critical materials for nuclear medicine, next-generation semiconductors, and nuclear energy.  ASPI employs proprietary ASP technology. ASPI’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. ASPI also plans to enrich isotopes for the nuclear energy sector using QE technology that ASPI is developing. ASPI has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).

 

Forward-Looking Statements

 

Statements contained herein relating to future plans, results, performance, expectations, achievements and the like are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the expected need or desire for HALEU and LEU+ by third parties, projections about the future nuclear fuel cycle for advanced nuclear reactors and fusion systems, as well as the existing nuclear fleet, the commencement of research, development and production activities in the United States, the future of the company’s enrichment technologies as applied to uranium enrichment, the outcome of the company’s initiative to commence enrichment of uranium in South Africa and the company’s discussions with nuclear regulators in South Africa and the UK, the outcome of the project contemplated with Necsa, QLE’s anticipated growth strategies and anticipated trends in QLE’s business, statements relating to QLE’s strategic partnerships or commercial initiatives and relationships with Fermi America, TerraPower and Necsa, statements related to the anticipated benefits to QLE and the collaboration resulting from the MOU discussed herein, and statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. These forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which may be beyond QLE’s or ASPI’s control, that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by any forward-looking statements.  All forward-looking statements speak only as of the date hereof. QLE and ASPI undertake no obligation to revise or update any forward-looking statements except as may be required by applicable law.

 

Contact

[email protected]

 

 
2